Voyager Therapeutics opened lower at $1.75, compared with its previous close of $1.76. In the last trading session, the stock traded between $1.71 and $1.78. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Voyager Therapeutics is now worth
$ 48.62
Resulting in a loss of
$ 51.38 (51.38%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.06 (-3.58%)
Day High
$1.78
Day Low
$1.71
Day Open
$1.75
Prev Close
$1.76
Volume
11,66,438
1W Return
-9.49%
1M Return
-24.75%
3M Return
-46.89%
6M Return
-58.81%
1Y Return
-60.16%
Fundamentals
Market Cap ($ Mn)
106
PE Ratio
-
PB Ratio
1.41
PEG Ratio
-
ROE
-48.58%
ROCE
-46.01%
EPS (TTM)
$-0.40
Investment Returns
1 Week
-9.49%
1 Month
-24.75%
3 Months
-46.89%
6 Months
-58.81%
9 Months
-53.51%
Financials
Quarterly
All values in $ Mn
6.5
Mar 25
5.2
Jun 25
13.4
Sep 25
15.3
Dec 25
3.2
Jun 26
4.0
Sep 26
Updates
1Sep
Voyager Therapeutics to present at five investor conferences in September
Voyager Therapeutics to hold fireside chats at five major healthcare conferences. Events span September 8 to September 15, 2026, in Boston and New York. Hosts include Wells Fargo, Cantor, Morgan Stanley, Baird, and H.C. Wainwright. Webcast of the Wells Fargo session will be archived for 30 days.
2mo ago
10Aug
HC Wainwright reiterates Buy on Voyager Therapeutics, keeps $25 target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates a Buy rating on Voyager Therapeutics (NASDAQ: VYGR). The firm maintains its $25 price target, indicating sustained bullish sentiment on the biotech stock without altering its previous valuation framework.
3mo ago
7Aug
Voyager Therapeutics Q2 EPS beats estimate despite sales miss
Voyager Therapeutics beat Q2 EPS estimates with $(0.40) per share but missed sales targets at $3.165 million. Net loss narrowed to $24.5 million due to reduced R&D and G&A expenses, while clinical trials for VY1706 advance.
3mo ago
13Jul
Voyager VY1706 shows 75% tau reduction in NHPs
Voyager Therapeutics reported that VY1706 achieved up to 75% reduction in tau protein in a six-month NHP study, with no adverse findings at the highest dose. The company secured FDA IND clearance in June and plans to begin dosing in a clinical trial for early Alzheimer’s disease in the second half of 2026.
4mo ago
12Jun
Voyager CEO to present at H.C. Wainwright Neuro conference
Voyager Therapeutics CEO Alfred W. Sandrock, Jr. will present at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference via a pre-recorded fireside chat. The webcast will be available on-demand starting June 15, 2026, at 7:00 a.m. ET and archived for 30 days. Voyager focuses on treating neurological diseases through genetic medicine, utilizing its TRACER™ platform.
